Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)

Source-based overview

The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases. The official record contains the controlling eligibility, budget, attachment and submission requirements for opportunity RFA-AI-28-024.

Eligibility

Eligible applicant types listed by the agency: Small businesses; Special district governments; For profit organizations other than small businesses; Native American tribal governments (Federally recognized); Others (see text field entitled "Additional Information on Eligibility" for clarification); County governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; City or township governments; Public and State controlled institutions of higher education; State governments; Independent school districts; Native American tribal organizations (other than Federally recognized tribal governments); Private institutions of higher education. Applicants must also satisfy every programme-specific condition in the official notice.

Funding and benefits

Award ceiling: See official notice

Themes and supported activities

The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases.

Opportunity number: RFA-AI-28-024

Deadline and timeline

Applications close 2027-02-11: Applications close 2027-02-11: Feb 11, 2027.

Applicants should confirm the exact deadline time, time zone, required documents, portal steps and any institutional approvals on the official call page before submitting.

How to apply

Open the official Grants.gov record, review the full notice and attachments, and use the application package or agency route stated there.

Before applying, check eligibility rules, budgets, attachments, page limits, partner requirements, cost-share conditions and whether the opportunity uses an expression of interest, full proposal, registration or nomination stage.